Literature DB >> 8587471

Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.

A J Trapani1, S De Lombaert, S Kuzmich, A Y Jeng.   

Abstract

The pharmacologic properties of CGS 26393, a prodrug of the endothelin-converting enzyme/neutral endopeptidase 24.11 inhibitor CGS 26303, were examined in conscious Sprague-Dawley rats. After oral administration of CGS 26393 at 30 mg/kg, the free concentrations of CGS 26303 in plasma were calculated to be 1.7 +/- 0.3, 1.2 +/- 0.2, and 0.31 +/- 0.05 microM at 4, 8, and 24 h, respectively. CGS 26393 inhibited the pressor response produced by exogenous big ET-1 in a dose-dependent manner. A 70% inhibition of the pressor response was observed when the prodrug was administered at 30 mg/kg p.o. As predicted by its pharmacokinetics, the inhibitory activity of CGS 26393 persisted for up to 8 h. These findings demonstrate that CGS 26393 in an orally active, long-acting ECE inhibitor in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587471

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein.

Authors:  Marcelo Campos; Constance Couture; Izaura Y Hirata; Maria A Juliano; Thomas P Loisel; Philippe Crine; Luiz Juliano; Guy Boileau; Adriana K Carmona
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

Review 2.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.

Authors:  E Y Yap; B Battistini; K O McKay
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

4.  Big ET-1 processing into vasoactive peptides in arteries and veins.

Authors:  Stephanie W Watts; Keshari Thakali; Chuck Smark; Catherine Rondelli; Gregory D Fink
Journal:  Vascul Pharmacol       Date:  2007-09-07       Impact factor: 5.773

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.